Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Psyence Australia Pty Ltd
Victoria, Australia
- Ownership
- Private
- Development stage
- Other
01
Overview
Psyence Biomedical is running a Phase IIb clinical trial in Australia for natural psilocybin-assisted therapy targeting adjustment disorder in palliative care cancer patients, with results expected in late 2025 and possible progression to Phase III. The company is also developing programs in substance use disorder (SUD) using ibogaine and maintains robust manufacturing partnerships for clinical supply.[2][3][4][6][8][10]
- Therapeutic areas
- Psychiatry
- Modalities
- Small moleculeNatural productPsychedelic-based therapy
- Industry
- Biotech
02
Partnerships
FluenceiNGENū CRO Pty LtdPsyLabsOptimi HealthFilament Health
Beyond the preview
Go deeper on Psyence Australia Pty Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Psyence Australia Pty Ltd.